Cellectar Biosciences Inc. (NASDAQ:CLRB) Stock Under Pressure: Down 55% This Year
Cellectar Biosciences Inc. (NASDAQ:CLRB) is down 55% so far this year. The company has completed its Part A section of the tolerability and safety study of iopofosine I-131 in conjunction with external beam radiation in refractory or relapsed head and neck cancer. The reduction infraction or amount of EBRT can possibly diminish the adverse events related to EBRT. Usually, head and neck cancer patients typically receive around 60-70 Grays for…